8/15 Early treatment study
et al., Complementary Therapies in Medicine, doi:10.1016/j.ctim.2021.102769 (Peer Reviewed)
Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
Nigella sativa for the treatment of COVID-19: An open-label randomized controlled clinical trial
RCT 183 mild COVID-19 outpatients in Saudi Arabia, 91 treated with Nigella Sativa, showing lower hospitalization and faster recovery with treatment. NCT04401202.500mg Nigella sativa oil (MARNYS Cuminmar) twice daily for 10 days.
risk of hospitalization, 74.7% lower, RR 0.25, p = 0.37, treatment 1 of 91 (1.1%), control 4 of 92 (4.3%).
risk of no recovery, 42.7% lower, RR 0.57, p < 0.001, treatment 34 of 91 (37.4%), control 60 of 92 (65.2%).
Koshak et al., 8/15/2021, Randomized Controlled Trial, Saudi Arabia, Middle East, peer-reviewed, 10 authors.
Effect extraction follows pre-specified rules
prioritizing more serious outcomes. For an individual study the most serious
outcome may have a smaller number of events and lower statistical significance,
however this provides the strongest evidence for the most serious outcomes
when combining the results of many trials.
Please send us corrections, updates, or comments. Vaccines and treatments are both extremely valuable and complementary. All
practical, effective, and safe means should be used. Elimination of COVID-19
is a race against viral evolution. No treatment, vaccine, or intervention is
100% available and effective for all current and future variants. Denying the
efficacy of any method increases the risk of COVID-19 becoming endemic; and
increases mortality, morbidity, and collateral damage. We do not provide
medical advice. Before taking any medication, consult a qualified physician
who can provide personalized advice and details of risks and benefits based
on your medical history and situation. Treatment protocols for physicians are
available from the FLCCC.